当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The Clinical Innovation Network: a policy for promoting development of drugs and medical devices in Japan
Drug Discovery Today ( IF 7.4 ) Pub Date : 2018-05-24 , DOI: 10.1016/j.drudis.2018.05.026
Shunsuke Matsushita , Keisuke Tachibana , Masuo Kondoh

The continuous increase in the costs of developing new drugs and medical devices drives increases in medical expenses. Seventy to ninety percent of these costs are associated with clinical trials. Therefore, the development of cost-effective methods to perform clinical trials remains a challenge. One approach is to use patient registries, collections of data related to patients with a specific diagnosis, condition, or procedure. Patient registries are used in Denmark, Sweden, and the USA for the enrollment of patients into clinical trials, and to evaluate endpoints. In Japan, a national project for registry-oriented clinical research, termed the ‘Clinical Innovation Network’ (CIN), was initiated in 2016. Here, we provide an overview of the CIN and discuss its impact on drug and device development in Japan.



中文翻译:

临床创新网络:在日本促进药物和医疗设备发展的政策

开发新药和医疗设备的成本不断增加,导致医疗费用增加。这些费用的百分之七十至百分之九十与临床试验有关。因此,开发具有成本效益的方法进行临床试验仍然是一个挑战。一种方法是使用患者注册表,收集与具有特定诊断,状况或程序的患者相关的数据。在丹麦,瑞典和美国使用患者注册表来将患者纳入临床试验并评估终点。在日本,于2016年启动了一项面向注册表的临床研究国家项目,称为“临床创新网络”(CIN)。在这里,我们提供了CIN的概述,并讨论了其对日本药物和设备开发的影响。

更新日期:2018-05-24
down
wechat
bug